@article{7ac7222f10f64382bacd25631eb5d2af,
title = "Reply to Ikeda and Tomita",
author = "Monica Tang and Mauger, {David T.} and Fahy, {John V.} and Dunican, {Eleanor M.}",
note = "Funding Information: Supported by Japan Society for the Promotion of Science KAKENHI grants 18K15928 and 22K08256. Funding Information: Supported by National Institutes of Health/National Heart, Lung, and Blood Institute sponsored network, grant R01 HL080414, P01 HL107202, U01 HL146002. The following companies provided financial support for study activities at the Coordinating and Clinical Centers beyond the third year of patient follow-up: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi– Genzyme–Regeneron, and TEVA. These companies had no role in study design or data analysis, and the only restriction on the funds was that they be used to support the SARP initiative. Funding Information: Supported by National Institutes of Health/National Heart, Lung, and Blood Institute sponsored network, grant R01 HL080414, P01 HL107202, U01 HL146002. The following companies provided financial support for study activities at the Coordinating and Clinical Centers beyond the third year of patient follow-up: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA. These companies had no role in study design or data analysis, and the only restriction on the funds was that they be used to support the SARP initiative. The authors thank Chuck E. McCulloch, Ph.D., Professor of Biostatistics and Former Head of the Department of Epidemiology and Biostatistics at UCSF, for assistance in formulating this response.",
year = "2022",
month = nov,
day = "15",
doi = "10.1164/rccm.202207-1337LE",
language = "English (US)",
volume = "206",
pages = "1299--1300",
journal = "American journal of respiratory and critical care medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",
}